@entity4854 in XXXX : frequency and associated lipid and lipoprotein levels in the @entity10569 infarction prevention (BIP) register. The BIP Study Group.

@entity1 @entity2298 @entity2175 @entity6 @entity301 @entity1602 @entity413 @entity951 @entity412 @entity74 @entity741 @entity10569 @entity583 @entity204 @entity4854 @entity65 @entity165
BACKGROUND: The lipid profile of @entity1 with @entity2175 is characterized by low levels of high-density lipoprotein @entity165 , @entity2298 , and increased levels of lipoprotein (a), all of which may affect the prognosis in @entity1 with @entity65 . This study aimed to assess the prevalence of asymptomatic @entity4854 and the associated lipid profile in a large group of @entity1 with documented @entity301 . METHODS: From February 1990 to October 1992, 14,326 @entity1 aged 45-74 years with documented @entity301 (a history of @entity583 or @entity951 ) were screened for inclusion in a secondary prevention study using @entity10569 retard. All screened @entity1 underwent a medical examination and a blood test after fasting for 14 h. @entity4854 was defined as a fasting blood @entity413 level of 140 mg/dl or above in @entity1 with no previous history of @entity6 . RESULTS: The prevalence of asymptomatic @entity4854 was 4%, with no differences between the sexes or age groups. Total @entity165 and @entity412 levels were significantly higher and the high-density lipoprotein @entity165 level significantly lower in asymptomatic @entity1602 than in normoglycemic @entity1 . After multiple adjustments, the relative risk of @entity204 was 1.75 and 1.71 in @entity1 with @entity6 or asymptomatic @entity4854 compared with those with no @entity74 . CONCLUSION: @entity4854 was detected in 4% of @entity1 with @entity741 . The lipid profile in these 4% resembles that of @entity1 with confirmed @entity6 , and their morbidity and mortality may therefore be higher than that of normoglycemic @entity1 . Repeated assessment of @entity413 levels in @entity1 with @entity301 is mandatory.
